41 results on '"Stahel, Rolf"'
Search Results
2. Strategies for improving outcomes in NSCLC: A look to the future
3. Treatment and detection of ALK-rearranged NSCLC
4. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
5. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage
6. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)
7. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy
8. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
9. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
10. Proteomic surfaceome analysis of mesothelioma
11. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
12. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma
13. Functional inactivation of NF2/merlin in human mesothelioma
14. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: Feasibility and responsiveness to clinical changes
15. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8
16. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results
17. Malignant pleural mesothelioma: A new standard of care
18. Cyclin D1 ( CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
19. Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer
20. Antisense oligonucleotides for cancer therapy—an overview
21. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors
22. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
23. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases
24. Neoadjuvant chemotherapy in malignant pleural mesothelioma
25. Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma
26. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation
27. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting
28. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)
29. P-606 Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss group for clinical cancer research (SAKK)
30. P-592 Neoadjuvant chemo- and radiotherapy in stage IIIA (N2) non-small cell lung cancer (NSCLC). Rationale for a radomized trial by the swiss group for clinical cancer research (SAKK)
31. O-200 Neoadjuvant chemotherapy followed by pleuropneumonectomy for pleural mesothelioma: a multicenter phase II trial of the SAKK
32. O-144 Result of a phase II study conducted in elderly patients with unresectable localised or metastatic non-small-cell-lung cancer (NSCLC) with oral vinorelbine given as a weekly monotherapy
33. Overview of the IASLC Mesothelioma workshop 2004
34. Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process
35. Chapter 30 Characterisation of small cell carcinoma surface membrane antigens by indirect immunofluorescence. Solid phase radioimmunoassay and immunoblotting
36. Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer
37. Biology of lung cancer
38. Staging and prognostic factors in small cell lung cancer: a consensus report
39. ME1-Antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies
40. Biologicals in the therapy of lung cancer
41. Chapter 6 Reactivity of SCLC associated monoclonals SWA4, SWA20 & SWA23 in formalin paraffin sections
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.